Latest Breaking News On - Anthony ditonno - Page 1 : comparemela.com

Tenax Therapeutics Announces Continuation of Board Refreshment Program as Three Long-Serving Directo

Search jobs 07-Apr-2021 Tenax Therapeutics Announces Continuation of Board Refreshment Program as Three Long-Serving Directors Volunteer to Not Stand for Re-Election at the Upcoming 2021 Annual Meeting of Stockholders MORRISVILLE, N.C. (BUSINESS WIRE) Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that Ronald R. Blanck, D.O., Gregory Pepin and Chris A. Rallis have voluntarily agreed to step down from the Board of Directors of Tenax Therapeutics, effective as of the Annual Meeting of Stockholders of Tenax, currently scheduled for June 10, 2021, retiring after years of service to the Board.

United statesJohn mullalyGregory pepinAnthony ditonnoRonaldr blanckOrion pharmaGerald proehlChrisa rallisExchange commissionLifesci advisorsOrion corporation of espoo finlandTenax therapeutics incPhyxius pharma incTenax therapeuticsAnnual meetingTenax board

Tenax Therapeutics Reports Fiscal Year 2020 Results and Provides Business Update

Tenax Therapeutics Reports Fiscal Year 2020 Results and Provides Business Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJohn mullalyDeclan dooganAnthony ditonnoOrion pharmaMichael davidsonJune almenoffLifesci advisorsRenal advisory committee memberBluhm cardiovascular instituteExchange commissionPulmonary vascular disease programOrion corporation of espoo finlandPhyxius pharma incTenax therapeutics incPulmonary hypertension

Tenax Therapeutics, Inc Expands Board of Directors

Published: Mar 02, 2021 New Board appointments strengthen Tenax with world-class expertise in cardiovascular drug development, commercial strategy, and business development New Directors will provide significant guidance as Tenax is poised to advance its two leading drug candidates into late-stage clinical testing Transformational step as Tenax strengthens its positioning as a leading specialty pharmaceutical company focused on cardio-pulmonary therapeutics a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high unmet medical need, today announced the appointment of four new members to its board of directors: June Almenoff, MD, PhD, Michael Davidson, MD, Delcan Doogan, MD, and Stuart Rich, MD.

Loyola university stritch school of medicineUnited statesNorthwestern universityUniversity of chicagoUniversity of illinois college medicineUniversity of illinoisDeclan dooganAnthony ditonnoOrion pharmaMichael davidsonDelcan dooganJune almenoffBoard of trusteesPrior to northwestern universityGlasgow university medical schoolPulmonary vascular research institute

Morrisville pharma Tenax buying firm with promising hypertension drug – shares soar 38%

MORRISVILLE –Tenax Therameputics is acquiring an Illinois-based biotech firm with a promising hypertension treatment and named that company’s cofounder as its chief medical officer. Tenax (Nasdaq: TENX) shares soared 38% to $2.45 shortly after the announced deal for PH Precision Med (PHPM) and the appointment of Stuart Rich, MD, as its CMO early Tuesday. Tenax is paying some 12 million shares of stock to PHPM shareholders. PHPM is focused on a potential treatment of pulmonary arterial hypertension, and its lead candidate has received Orphan Drug Designation from the FDA. The drug – a “Pase 3 [clinical trial] candidate” – has the “potential to be the first disease modifying treatment of pulmonary arterial hypertension,” Tenax explained.

United statesDeclan dooganAnthony ditonnoTenax therameputicsMichael davidsonPulmonary vascular disease programRenal advisory committee memberBluhm cardiovascular instituteStuart richOrphan drug designationNorthwestern university feinberg schoolBluhm cardiovascularNasdaq ruleஒன்றுபட்டது மாநிலங்களில்டெக்லான் தூகண்மைக்கேல் டேவிட்சன்

Aclaris Therapeutics (NASDAQ:ACRS), Celyad SA (NASDAQ:CYAD) - Why Aclaris, Tenax, Gritstone, Merus, Minerva And Celyad Are Rallying Today

Aclaris Therapeutics (NASDAQ:ACRS), Celyad SA (NASDAQ:CYAD) - Why Aclaris, Tenax, Gritstone, Merus, Minerva And Celyad Are Rallying Today
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Anthony ditonnoEli lilly and coAclaris therapeutics incGritstone oncology incGates foundationDepression drug minerva neurosciences incTenax therapeutics incOncology dealWeek ahead in biotechCelyad oncologyCancers symposiumஎலி லில்லி மற்றும் இணைவாயில்கள் அடித்தளம்மனச்சோர்வு மருந்து மினெர்வா நரம்பியல் இன்க்புற்றுநோயியல் ஒப்பந்தம்புற்றுநோய்கள் சிம்போசியம்